Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2016/V13/I7/445

[1] Li A, Wong C S, Wong M K, et al. Acute adverse reactions to magnetic resonance contrast media--gadolinium chelates [J]. Br J Radiol. 2006;79(941):368-371.
[2] 王宇，陈伟，杨珺．钆喷酸葡胺注射液不良反应的文献分析[J]．中国药物警戒，2013，10(12):749-751．
[3] 刘松岩，战心，徐辉，等．我院钆喷酸葡胺对比剂致8例不良反应分析[J]．中国药房，2011，22(20):1899-1900.
[4] 周丽华，张蕾，白俊萍．钆喷酸葡胺注射液致过敏性休克1例[J]. 药物流行病学杂志，2013，22(10):577．
[5] 韩晋,吴荣荣. 钆喷酸葡胺注射液引起过敏性休克死亡1例[J]. 中国药物应用与监测,2009,6(6):373.
[6] Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment[EB/OL].(2012-04-17)[2016-05-19]. http://www.who-umc.org/Graphics/26649.pdf.
[7] 胡朝芬.磁共振成像造影剂的增强机制与临床应用[ J] .实用放射学杂志, 2002, 18(5):431-434.
[8] 吴满生.核磁共振成像钆对比剂不良反应的观察及护理[J].全科护理,2011,9(8):2177.
[9] Neidorf H D, Haustein J, Comelius I, et al. Safety of gadolinium DTPA: extended clinical experience [J]. MagnReson Med, 1991, 22(2): 222-228.
[10] De Ridder F, De Maeseneer M, Stadnik T, et al．Severe adverse reactions with contrast agents for magnetic resonance: clinical experience in 30000 MR examinations [J]. JBR-BTR, 2001, 84 (4) : 150-152.
[11] 李信华. 47例钆喷酸葡胺注射液不良反应的文献分析[J].中南药学,2016,14(3):333-335.
[12] 任转琴，王景安，齐秋绪，等.顺磁对比剂在低场MRI中的诊断价值（附406例分析）[J].实用放射学杂志，2002，18（9）；806.
[13] Ahn Y H, Koh Y I, Kim J H, et al. The potential utility of iodinated contrast media (ICM) skin testing in patients with ICM hypersensitivity [J]. J Korean Med Sci, 2015, 30(3):245-251.
[14] 任力杰，韩漫夫，雷益．钆喷酸葡胺对比剂的安全性再评价—附5例不良反应分析[J]．罕少疾病杂志，2007，14(3):38-40．
[15] Baig M, Farag A, Sajid J, et al. Shellfish allergy and relation to iodinatedcontrastmedia: United Kingdom survey [J]. World J Cardiol,2014, 6(3):107-111.
[16] Ring J, Beyer K, Biedermann T, et al. Guideline for acute therapy andmanagement of anaphylaxis[J]. Allergo J Int.2014;23 (3):96-112.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.